Novocure Highlights Presentation Of Final Safety And Efficacy Results From Phase 2 Pilot HEPANOVA Trial In Liver Cancer; Disease Control Rate With 76% With 9.5% Objective Response Rate
Disease control rate was 76% with 9.5% objective response in a patient population with poor prognosis and limited exposure to study treatments
In patients who completed at least 12 weeks of Tumor
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment.
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 24)
Stocks That Hit 52-Week Highs On Thursday
Before 10 a.m. ET on Thursday, 145 companies set new 52-week highs.
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira’s CEO Placed On Temporary Leave, 5 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)
Novocure Initiates Usability Study For Flexible Torso Array
New array intended to increase ease-of-use for torso and abdominal applications
Novocure (NASDAQ:NVCR) today announced it has advanced a new, flexible torso array into a clinical usability study. The updated array will
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 14)
Stocks That Hit 52-Week Highs On Monday
During Monday's morning session, 255 companies made new 52-week highs.
Novocure Announces FDA IDE Approval And Steering Committee For KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together With Pembrolizumab In Non-Small Cell Lung Cancer
Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer
Novocure (NASDAQ:NVCR) today announced that the